Phase I Clinical Study Of The Recombinant Antibody-Toxin Scfv (Frp5)-Etaspecific For The Erbb2/Her2 Receptor In Patients With Advanced Solid Malignomas (Vol 7, Pg R617, 2005)
BREAST CANCER RESEARCH(2006)
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined